The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

Melinda J. Gooderham, MSc, MD,1 Leon H. Kircik, MD,2 Matthew Zirwas, MD,3 Mark Lee, MD,4 Steven E. Kempers, MD,5 Zoe D. Draelos, MD,6 Laura K. Ferris, MD, PhD,7 Terry M. Jones, MD,8 Etienne Saint-Cyr Proulx, MD,9 Robert Bissonnette, MD,9 Neal Bhatia, MD,10 Scott T. Guenther, MD,11 Robert A. Koppel, MD,12 Howard Welgus, MD,13 Charlotte Merritt, MBA,13 Meg Elias, BSN,13 Lynn Navale, MS,13 Robert C. Higham, MPAS, PA-C,13 Michael Droge, PhD,13 David R. Berk, MD13

1SKiN Centre for Dermatology, Probity Medical Research and Queen’s University, Peterborough, ON, Canada; 2Icahn School of Medicine at Mount Sinai, NY; Indiana Medical Center, Indianapolis, IN; Physicians Skin Care, PLLC, Louisville, KY; and Skin Sciences, PLLC, Louisville, KY, USA; 3Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA; 4Progressive Clinical Research, San Antonio, Texas, USA; 5Minnesota Clinical Study Center, Fridley, MN, USA; 6Dermatology Consulting Services, PLLC, High Point, NC, USA; 7University of Pittsburgh, Department of Dermatology, Pittsburgh, PA, USA; 8US Dermatology Partners, Bryan, TX, USA; 9Innovaderm Research, Montreal, QC, Canada; 10Therapeutics Clinical Research, San Diego, CA, USA; 11The Dermatology Center of Indiana, PC; The Indiana Clinical Trials Center, PC, Plainfield, IN, USA; 12Clinical Trials Management, LLC, Metairie, LA, USA; Tulane University School of Medicine in New Orleans, LA, USA; 13Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA

Introduction & Objectives
Atopic dermatitis (AD) is commonly treated with topical anti-inflammatory therapy (corticosteroids or calcineurin inhibitors) in combination with emollients. However, side effects limit long-term use of topical corticosteroids and alternative treatments are needed. Roflumilast cream (ARQ-151) is a highly potent phosphodiesterase-4 (PDE-4) inhibitor with ~25- to >300-fold higher potency than the approved PDE-4 inhibitors, crisaborole and apremilast. Roflumilast cream 0.3% is currently in Phase 3 development for plaque psoriasis. The objective of this Phase 2, proof-of-concept study was to assess the safety and efficacy of once-daily (QD) roflumilast 0.15% and 0.05% in patients with mild to moderate AD.

Materials & Methods
This randomized, parallel-group, double-blind, vehicle-controlled study enrolled 136 patients (≥12 years of age) from North America who had 1.5-35% body surface area (BSA) affected by AD, with a validated investigator global assessment-AD (vIGA-AD) score of 2 (mild) or 3 (moderate), and eczema area and severity index (EASI) score of ≥5. Patients were randomized (1:1:1) to roflumilast 0.15%, roflumilast 0.05% or vehicle QD for 4 weeks. The primary efficacy endpoint was absolute change from baseline in EASI score at Week 4. Other efficacy assessments included EASI percent change from baseline and responder rates, and vIGA-AD. Safety was evaluated through local tolerability assessments and adverse events (AEs). Testing of secondary endpoints was not adjusted for multiplicity.
Results
At baseline, 22.1% of patients had a vIGA-AD of mild, 77.9% had a vIGA-AD of moderate, and mean BSA was 9.5%. Completion rate was over 90% in all treatment groups. At Week 4, the mean changes in EASI scores from baseline of 9.5, 8.4, and 9.2 were -6.4 ($P=0.097$ compared with vehicle), -6.0 ($P=0.356$), and -4.8 with roflumilast 0.15%, roflumilast 0.05%, and vehicle, respectively (primary endpoint; Figure). Statistically significant improvements compared with vehicle were observed at Week 4 for % change from baseline in EASI score (-72.3% [$P=0.049$], -69.4% [$P=0.164$], and -55.8% for roflumilast 0.15%, roflumilast 0.05%, and vehicle, respectively); patients reaching EASI-75 (52.3% [$P=0.045$], 59.1% [$P=0.009$], and 31.1%); and patients achieving vIGA-AD score of clear or almost clear (52.3% [$P=0.040$], 50.0 [$P=0.076$], and 31.1%; Figure). At Week 4, there was no evidence of efficacy plateau as measured by EASI and vIGA-AD. Overall, 4 patients experienced a treatment-related TEAE: none in the roflumilast 0.15% group, 2 patients (4.3%) in the roflumilast 0.05% group, and 2 patients (4.4%) in the vehicle group. All TEAEs were mild or moderate. Only 2 patients (1 in roflumilast 0.05% and 1 in vehicle group) discontinued study drug due to an AE. Application site pain was reported in just 2 patients: 1 (2.2%) in the roflumilast 0.05% group and 1 (2.2%) in the vehicle group.

Discussion
In this small, proof-of-concept study, the primary endpoint showed a trend towards, but did not reach, statistical significance. However, statistical significance was reached for other efficacy endpoints including % change from baseline in EASI score, EASI-75 responders, and patients achieving vIGA-AD score of clear or almost clear. Both doses of roflumilast (0.15% and 0.05%) had a favorable safety profile, with a low rate of application site reactions. This study suggests that roflumilast cream, a potent PDE-4 inhibitor, represents a potential effective QD treatment for AD.

![Figure. Primary (A), secondary (B, C), and exploratory (D) efficacy endpoints.](image-url)